Your browser doesn't support javascript.
loading
Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex.
Strickson, Sam; Houslay, Kirsty F; Negri, Victor A; Ohne, Yoichiro; Ottosson, Tomas; Dodd, Roger B; Huntington, Catherine Chaillan; Baker, Tina; Li, Jingjing; Stephenson, Katherine E; O'Connor, Andy J; Sagawe, J Sophie; Killick, Helen; Moore, Tom; Rees, D Gareth; Koch, Sofia; Sanden, Caroline; Wang, Yixin; Gubbins, Elise; Ghaedi, Mahboobe; Kolbeck, Roland; Saumyaa, Saumyaa; Erjefält, Jonas S; Sims, Gary P; Humbles, Alison A; Scott, Ian C; Romero Ros, Xavier; Cohen, E Suzanne.
Afiliación
  • Strickson S; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Houslay KF; These authors contributed equally to this work.
  • Negri VA; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Ohne Y; These authors contributed equally to this work.
  • Ottosson T; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Dodd RB; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Huntington CC; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Baker T; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Li J; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Stephenson KE; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • O'Connor AJ; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Sagawe JS; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Killick H; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Moore T; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Rees DG; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Koch S; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Sanden C; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Wang Y; Imaging & Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
  • Gubbins E; Experimental Medical Sciences, Lund University, Lund, Sweden.
  • Ghaedi M; Medetect AB, Lund, Sweden.
  • Kolbeck R; Imaging & Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Saumyaa S; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Erjefält JS; Bioscience COPD/IPF, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Sims GP; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Humbles AA; Current: Spirovant Sciences, Philadelphia, PA, USA.
  • Scott IC; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Romero Ros X; Experimental Medical Sciences, Lund University, Lund, Sweden.
  • Cohen ES; Allergology and Respiratory Medicine, Lund University, Skåne University Hospital, Lund, Sweden.
Eur Respir J ; 62(3)2023 09.
Article en En | MEDLINE | ID: mdl-37442582
ABSTRACT

BACKGROUND:

Epithelial damage, repair and remodelling are critical features of chronic airway diseases including chronic obstructive pulmonary disease (COPD). Interleukin (IL)-33 released from damaged airway epithelia causes inflammation via its receptor, serum stimulation-2 (ST2). Oxidation of IL-33 to a non-ST2-binding form (IL-33ox) is thought to limit its activity. We investigated whether IL-33ox has functional activities that are independent of ST2 in the airway epithelium.

METHODS:

In vitro epithelial damage assays and three-dimensional, air-liquid interface (ALI) cell culture models of healthy and COPD epithelia were used to elucidate the functional role of IL-33ox. Transcriptomic changes occurring in healthy ALI cultures treated with IL-33ox and COPD ALI cultures treated with an IL-33-neutralising antibody were assessed with bulk and single-cell RNA sequencing analysis.

RESULTS:

We demonstrate that IL-33ox forms a complex with receptor for advanced glycation end products (RAGE) and epidermal growth factor receptor (EGFR) expressed on airway epithelium. Activation of this alternative, ST2-independent pathway impaired epithelial wound closure and induced airway epithelial remodelling in vitro. IL-33ox increased the proportion of mucus-producing cells and reduced epithelial defence functions, mimicking pathogenic traits of COPD. Neutralisation of the IL-33ox pathway reversed these deleterious traits in COPD epithelia. Gene signatures defining the pathogenic effects of IL-33ox were enriched in airway epithelia from patients with severe COPD.

CONCLUSIONS:

Our study reveals for the first time that IL-33, RAGE and EGFR act together in an ST2-independent pathway in the airway epithelium and govern abnormal epithelial remodelling and muco-obstructive features in COPD.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad Pulmonar Obstructiva Crónica / Interleucina-33 Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Eur Respir J Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad Pulmonar Obstructiva Crónica / Interleucina-33 Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Eur Respir J Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido
...